APA引文

Ou, S., Soo, R., Kubo, A., Kawaguchi, T., Ahn, M., & SINGAPORE, C. S. I. O. (2020). Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

Chicago Style Citation

Ou, S.-H.I, R.A Soo, A. Kubo, T. Kawaguchi, M.-J Ahn, and CANCER SCIENCE INSTITUTE OF SINGAPORE. Will the Requirement By the US FDA to Simultaneously Co-develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-small Cell Lung Cancer Globally? 2020.

MLA引文

Ou, S.-H.I, et al. Will the Requirement By the US FDA to Simultaneously Co-develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-small Cell Lung Cancer Globally? 2020.